Alnylam Pharmaceuticals, Inc. (ALNY)
AI stock analysis · as of Jul 31, 2026
Loading microstructure…
Alnylam Pharmaceuticals is a commercial-stage RNAi therapeutics leader whose TTR franchise (AMVUTTRA/ONPATTRO) is scaling rapidly following the March 2025 FDA cardiomyopathy label expansion, with revenue up ~65% YoY and the company crossing into GAAP profitability in 2025. The core investment question is whether a post-earnings ~29% drawdown, driven by a Q2 2026 guidance cut on second-line AMVUTTRA normalization, represents a discounted entry into a durable 25%+ CAGR compounder with a broad late-stage pipeline (nucresiran, zilebesiran, cemdisiran, mivelsiran) — or whether competitive pressure from tafamidis and acoramidis plus a slowing demand curve is starting to structurally cap the ATTR-CM opportunity.
valuationCheap on forward earnings and growth-adjusted metrics (fwd PE 15.6x, PEG 0.52, P/S ~6.4x against ~65-96% revenue growth and 23% operating margins), but optically expensive on EV/EBITDA (47x) and P/B (25.5x); the disconnect reflects a rapid transition to profitability that trailing multiples have not caught up to.
This analysis is from Jul 31, 2026. Want the latest on ALNY, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Revenue inflection is real: 2025 revenue of $3.71B was up 65% YoY with the company flipping from a $278M net loss in 2024 to $314M net income and $465M FCF, validating operating leverage toward the 30% non-GAAP margin 2030 target
- · AMVUTTRA CM label expansion (FDA March 2025, EC June 2025, plus Brazil/Japan/UK/Canada) multiplies the addressable ATTR population several-fold vs. the prior polyneuropathy-only indication and AMVUTTRA has now crossed $1B quarterly run-rate
- · Forward PE of 15.6x and PEG of 0.52 are unusually cheap for a specialty biopharma growing revenue ~96% with 23% operating margins and 90% ROE — the multiple compression from the sell-off has decoupled from fundamentals
- · Deep late-stage pipeline provides multiple shots on goal: nucresiran (twice-yearly dosing best-in-class potential), zilebesiran Phase 3 ZENITH with Roche, cemdisiran hit Phase 3 primary endpoint in myasthenia gravis with Q1 2026 submission, and mivelsiran advancing in Alzheimer's/CAA
- · Balance sheet flexibility with $1.66B cash, new 0% coupon 2028 notes refinancing near-term maturities, and an undrawn $500M revolver — funding pipeline execution without near-term dilution pressure
- · Consensus target of $427.61 (23 analysts, buy rating) sits more than 2x the current $205 price, implying the sell-side has not capitulated on the long-term thesis
Bear case
- · The Q2 2026 guidance cut on second-line AMVUTTRA demand normalization suggests the initial CM launch bolus may be more front-loaded than expected, and Needham cut its target to $357 in response
- · Direct competition in ATTR-CM from Pfizer tafamidis (entrenched incumbent) and BridgeBio acoramidis (newly launched oral) threatens AMVUTTRA share gains in the segment driving nearly all of the growth story
- · Debt-to-equity of 276 is extreme; the Blackstone royalty funding obligation on vutrisiran/zilebesiran plus $362.8M of 2027 notes still outstanding creates contingent liabilities that will bite if pipeline execution slips
- · EV/EBITDA of 47x and P/B of 25.5x show the stock is still not statistically cheap on trailing metrics — the bull case relies entirely on forward growth being delivered
- · Revenue concentration in the TTR franchise means any safety signal, label restriction, or IRA pricing pressure on AMVUTTRA disproportionately impacts the whole story
- · Stock is down ~59% from the $495 52-week high, reflecting a clear break in momentum; Jefferies most recent action (March 2026) was a downgrade
Catalysts
- · Next earnings on July 30, 2026 — critical for whether the guidance cut was a one-time reset or the start of a trend in AMVUTTRA net adds
- · Cemdisiran U.S. regulatory submission in Q1 2026 for myasthenia gravis (with Regeneron), potential first non-TTR approval broadening the revenue base
- · Zilebesiran Phase 3 ZENITH cardiovascular outcomes readouts — a hypertension RNAi success would be a massive TAM expansion beyond rare disease
- · Nucresiran Phase 3 progression toward ATTR-PN filing by 2028 with twice-yearly dosing that could leapfrog AMVUTTRA and defend against oral competitors
- · Short interest at 5.77% of float with 3.6 days to cover — not extreme but meaningful enough to amplify any positive surprise
- · Continued geographic expansion of AMVUTTRA-CM approvals and Leqvio royalty ramp (now in 108 countries)
Key risks
- · Further AMVUTTRA demand deceleration as tafamidis/acoramidis competition intensifies in ATTR-CM through 2026-2027
- · Phase 3 failure in nucresiran, zilebesiran, or mivelsiran — any one would materially impair the 2030 growth algorithm
- · IRA drug price negotiation and payer pushback on ultra-rare disease list prices compressing net realized pricing
- · Convertible note refinancing/dilution risk on the $661.3M 2028 notes plus residual 2027 notes if equity remains depressed
- · Manufacturing disruption at contract siRNA manufacturers given complex production requirements
- · IP challenges to GalNAc conjugate/LNP delivery platforms eroding the moat
What to watch
- · July 30, 2026 earnings — AMVUTTRA net adds, guidance revision direction, and management commentary on CM competitive dynamics
- · Cemdisiran FDA submission and PDUFA timeline updates in Q1-Q2 2026
- · Any Pfizer tafamidis or BridgeBio acoramidis prescription trend data that reads across to AMVUTTRA share
- · Key technical level: the $262 52-week low — a break below would signal continued distribution
- · Zilebesiran interim safety/enrollment updates from Phase 3 ZENITH
- · Insider buying activity — the 19 insider transactions with zero net selling over 180d suggests no capitulation from management; watch for actual open-market buys as a confidence signal
Key metrics
Price target rationale
Base case ~$290 applies ~18x forward PE on modestly reset 2026 EPS assumptions plus pipeline optionality, in line with the analyst low-end $310. Bull case $380 assumes AMVUTTRA-CM re-accelerates and cemdisiran approval, warranting ~22x forward PE. Bear case $165 assumes further guidance cuts, competitive share loss, and a 12x forward PE compression consistent with derating specialty pharma peers facing top-line pressure.
On Wall Street's view (mixed): The $427.61 consensus target (>2x current price) likely overstates near-term upside given the guidance cut and CM competitive dynamics, but is directionally right that the sell-off has overshot fundamentals. A base case in the $270-310 range is more defensible than either the low-end $310 or mean $427.
Latest filing (10-K)
Alnylam is riding a major commercial inflection as AMVUTTRA's new cardiomyopathy label opens a vastly larger TTR market, while a deep pipeline including nucresiran, zilebesiran, and cemdisiran positions the company to compound growth well beyond its current rare-disease base toward its 2030 targets of 25%+ revenue CAGR and 30% operating margins.
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that develops and sells RNAi (RNA interference) therapeutics, which silence disease-causing genes using small interfering RNA molecules. The company generates revenue from direct product sales of four marketed medicines (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO), collaboration and licensing agreements with partners including Roche, Regeneron, and Novartis, and royalties on partner-commercialized products like Leqvio (inclisiran, sold by Novartis) and Qfitlia (fitusiran, sold by Sanofi). Its Alnylam 2030 strategy targets 25%+ total revenue CAGR and approximately 30% non-GAAP operating margin by end of 2030.
What the news says · bearish
Alnylam's Q2 2026 earnings triggered a sharp sell-off of roughly 25-30%, driven primarily by a guidance cut as second-line AMVUTTRA demand normalizes — despite headline revenue jumping 67% YoY and AMVUTTRA crossing the $1B quarterly milestone. The market is punishing the forward outlook miss rather than the strong historical growth, with Needham lowering its price target to $357. Multiple valuation models (GF Value) flag the stock as deeply undervalued post-plunge, and the pipeline — including new trials for bleeding disorders and Alzheimer's — offers longer-term optionists, but near-term sentiment is clearly negative. Coverage is concentrated on a single earnings event, so the bearish read is event-driven rather than a structural deterioration thesis.
This analysis is from Jul 31, 2026. Markets move. Get the current read on ALNY and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.